You're currently on:

Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients

Double click on above image to view full picture

Zoom Out
Zoom In

More Views

Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients

Availability: In stock.

$20.00
Add Items to Cart
Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients

Description

Flaws in the U.S. Food and Drug Administration's Rationale for Supporting the Development and Approval of BiDil as a Treatment for Heart Failure Only in Black Patients

Additional Information

Author George T. H. Ellison, Jay S. Kaufman, Rosemary F. Head, Paul A. Martin, Jonathan D. Kahn
Number 3
Volume 36
Publication JLME
Journal Year 2008
 

My Cart

You have no items in your shopping cart.